Emerging drugs for migraine treatment

Bibliography

• Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992;12:221-8
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9
   PubMed Web of Science ®Google Scholar
• Martelletti P, Birbeck GL, Katsarava Z, et al. The global burden of disease survey 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain 2013;14:13
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369:448-57
   PubMed Web of Science ®Google Scholar
• Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53(3):427-36
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-15
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45:S3-13
   Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808
   PubMed Web of Science ®Google Scholar
• Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011;51(Suppl 2):77-83
   PubMedGoogle Scholar
• Affaitati G, Fabrizio A, Savini A, et al. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 2009;31:705-20
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol 2011;25:185-98
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Tafuri E, Savini A, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain 2007;8:869-78
   PubMed Web of Science ®Google Scholar
• Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17:393-406
   PubMed Web of Science ®Google Scholar
• Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol 2014;1-3; Epub ahead of print
   Google Scholar
• Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 2013;93:78-85
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12:570-84
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The vascular theory of migraine – a great story wrecked by the facts. Brain 2009;132(Pt 1):6-7
   PubMedGoogle Scholar
• Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs 2014;28:11-17
   PubMed Web of Science ®Google Scholar
• Sabato D, Lionetto L, Martelletti P. The therapeutic potential of novel anti-migraine acute therapies. Expert Opin Investig Drugs 2014;1-4; Epub ahead of print
   Google Scholar
• Belvis R, Mas N, Aceituno A. Migraine attack treatment: a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov 2014;9:26-40
   PubMedGoogle Scholar
• Negro A, Napoletano F, Lionetto L, et al. Treatment of menstrual migraine: utility of control of related mood disturbances. Expert Rev Neurother 2014;14:493-502
   PubMed Web of Science ®Google Scholar
• Vollbracht S, Rapoport AM. The pipeline in headache therapy. CNS Drugs 2013;27:717-29
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med 2002;346:257-70
   PubMed Web of Science ®Google Scholar
• Rizzoli PB. Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat 2014;10:547-52
   PubMed Web of Science ®Google Scholar
• Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies. Expert Opin Drug Discov 2013;8:1309-23
   PubMed Web of Science ®Google Scholar
• Tana C, Santilli F, Martelletti P, et al. Correlation between Migraine Severity and Cholesterol Levels. Pain Pract 2014; doi:10.1111/papr.12229. [Epub ahead of print]
   PubMedGoogle Scholar
• Tana C, Tafuri E, Tana M, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain 2013;14(1):9
   PubMedGoogle Scholar
• Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014;15:1863-74
   PubMed Web of Science ®Google Scholar
• Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004;84:903-34
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Gulbenkian S, Barroso CP, et al. Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 1998;19:1213-25
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010;169:683-96
   PubMed Web of Science ®Google Scholar
• Hokfelt T, Arvidsson U, Ceccatelli S, et al. Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems. Ann N Y Acad Sci 1992;30:119-34
   Google Scholar
• van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997;21:649-78
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-6
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61
   PubMed Web of Science ®Google Scholar
• Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004;142:1171-81
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007;13:39-44
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Warfvinge K. CGRP receptor antagonism and migraine therapy. Curr Protein Pept Sci 2013;14:386-92
   PubMed Web of Science ®Google Scholar
• Vécsei L, Szok D, Csáti A, Tajti J. CGRP antagonists and antibodies for the treatment of migraine. Expert Opin Investig Drugs 2015;24:31-41
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010;30:1159-69
   PubMed Web of Science ®Google Scholar
• Olesen J. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks. Cephalalgia 2010;30:1157-8
   PubMed Web of Science ®Google Scholar
• Ramadan NM. The link between glutamate and migraine. CNS Spectr 2003;8:446-9
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Pihl T, Hougaard A, Mitsikostas DD. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 2014;23:375-85
   PubMed Web of Science ®Google Scholar
• Deval E, Gasull X, Noel J, et al. Acid-sensing ion channels (ASICs): pharmacology and implication in pain. Pharmacol Ther 2010;128:549-58
   PubMed Web of Science ®Google Scholar
• Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-92
   PubMed Web of Science ®Google Scholar
• Dussor G, Yan J, Xie JY, et al. Targeting TRP channels for novel migraine therapeutics. ACS Chem Neurosci 2014;5:1085-96
   PubMed Web of Science ®Google Scholar
• Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007;27:394-402
   PubMed Web of Science ®Google Scholar
• Benemei S, Fusi C, Trevisan G, Geppetti P. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol 2014;171:2552-67
   PubMed Web of Science ®Google Scholar
• Nicoletti P, Trevisani M, Manconi M, et al. Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 2008;28:9-17
   PubMed Web of Science ®Google Scholar
• Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. BJU Int 2008;101:2-6
   PubMed Web of Science ®Google Scholar
• Lima AM, Sapienza GB, Giraud Vde O, Fragoso YD. Odors as triggering and worsening factors for migraine in men. Arq Neuropsiquiatr 2011;69:324-7
   PubMed Web of Science ®Google Scholar
• Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol 2006;95:1298-306
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M, Garcia-Nicas E, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 2010;68:81-91
   PubMed Web of Science ®Google Scholar
• Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain 2013;154(Suppl 1):S44-53
   PubMed Web of Science ®Google Scholar
• De Col R, Koulchitsky SV, Messlinger KB. Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus. Neuroreport 2003;14:229-32
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995;682:167-81
   PubMed Web of Science ®Google Scholar
• Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000;123(Pt 8):1703-9
   PubMed Web of Science ®Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24
   PubMed Web of Science ®Google Scholar
• Lin Q, Palecek J, Paleckova V, et al. Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. J Neurophysiol 1999;81(3):1075-85
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr Opin Neurol 2001;14:315-21
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350(11):1104-10
   PubMed Web of Science ®Google Scholar
• Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73(12):970-7
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebocontrolled, parallel-treatment trial. Lancet 2008;372(9656):2115-23
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70(16):1304-12
   PubMed Web of Science ®Google Scholar
• Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 2011;51:73-84
   PubMed Web of Science ®Google Scholar
• Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol 2010;50:1367-76
   PubMed Web of Science ®Google Scholar
• Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014;83:958-66
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011;31(6):712-22
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011;31:573-84
   PubMed Web of Science ®Google Scholar
• Bigal ME. BMS-927711 for the acute treatment of migraine. Cephalalgia 2014;34:90-2
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014;34:114-25
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014;28:389-99
   PubMed Web of Science ®Google Scholar
• Zhu DXD, Zhang J, Zhou L, et al. A human CGRP receptor antagonist antibody, AA95, is effective in inhibiting capsaicin-induced increase in dermal blood flow in cynomolgus monkeys. Headache 2012;52:871-2
   Web of Science ®Google Scholar
• Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 2008;155:1093-103
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014;13:885-92
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014;13:1100-7
   PubMed Web of Science ®Google Scholar
• Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs 2014;6:871-8
   PubMed Web of Science ®Google Scholar
• Bigal M, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia 2013;34:483-92
   Web of Science ®Google Scholar
• Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014;34:968-76
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT[1F]) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001;358:1230-4
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – a randomised proof-of-concept trial. Cephalalgia 2010;30:1170-8
   PubMed Web of Science ®Google Scholar
• Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a Phase II randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13
   PubMed Web of Science ®Google Scholar
• Holland PR, Akerman S, Andreou AP, et al. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol 2012;72:559-63
   PubMed Web of Science ®Google Scholar
• Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting TRPA1 channel. Pain 2013;154:2750-8
   PubMed Web of Science ®Google Scholar
• Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition in migraine. Lancet 1997;349:401-2
   PubMed Web of Science ®Google Scholar
• Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics 2010;7:183-90
   PubMed Web of Science ®Google Scholar
• Hoivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010;30:1458-67
   PubMed Web of Science ®Google Scholar
• Høye KLB, Harnisch LO, Twomey CK, et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia 2009;29:132
   Google Scholar
• Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 2009;29:124
   Google Scholar
• Bhatt DK, Gupta S, Jansen-Olesen I, et al. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia 2013;33:87-100
   PubMed Web of Science ®Google Scholar